Vinogradova T I, Aleksandrova A E, Antonenkova E V, Elokhina V N, Nakhmanovich A S
Probl Tuberk. 1999(3):45-7.
Studies dealing with the design of new antituberculous agents based on goal-oriented synthesis have provided the agent Perchlosone which is similar to isoniazid and rifampicin, produces in tuberculostatic activity against sensitive laboratory cultured mycobacteria, produces an inhibitory action on polyresistant clinical strains. Experiments on animals (mice, rabbits) with experimental tuberculosis have established that Perchlosone and isoniazid have equal therapeutical properties, and the former shows a synergist interaction with rifampicin, has neither mutagenic activity nor negative effects on immunity and the surfactant system of the lung.
基于目标导向合成设计新型抗结核药物的研究已开发出氯高松,它与异烟肼和利福平相似,对实验室培养的敏感分枝杆菌具有抑菌活性,对多重耐药临床菌株有抑制作用。在患有实验性结核病的动物(小鼠、兔子)身上进行的实验表明,氯高松和异烟肼具有相同的治疗特性,前者与利福平具有协同相互作用,既无诱变活性,也对免疫力和肺表面活性物质系统无负面影响。